Virtual Investor is a leading platform providing investors with direct access to innovative companies, management teams and thought leaders.
Covered Companies
Covered Companies
Series
What This Means
Featuring Ernexa Therapeutics
November 6, 2025
Sanjeev Luther, President and CEO of Ernexa, discusses the Company’s recently announced partnership agreement with Cellipont Bioservices focused on Engineering, Differentiation, and Production (EDP) activities to advance ERNA-101, Ernexa’s lead cell therapy for the treatment of ovarian cancer, into clinical manufacturing and clinical trials.
What This Means
Featuring HCW Biologics
October 22, 2025
Dr. Peter Rhode, PhD, Chief Scientific Officer and Vice President of Clinical Operations of HCW Biologics, discusses the Company’s lead product candidate, known as HCW11-040, which is the Company’s franchise immunotherapeutic for internal clinical development as a second-generation immune checkpoint inhibitor.
What This Means
Featuring HCW Biologics
September 30, 2025
Dr. Peter Rhode, PhD, Chief Scientific Officer and Vice President of Clinical Operations of HCW Biologics discusses the Company’s recent news announcing its second-generation T-Cell Engager program. The Company has joined a small group of innovative biotechnology companies who have discovered new compounds that overcome resistance mechanisms and improve the ability to treat solid tumors.
What This Means
Featuring: enVVeno Medical
September 26, 2025
Rob Berman, CEO discusses the Company’s recent news announcing it filed a request for supervisory appeal of the not-approvable letter from the Center for Devices and Radiological Health (CDRH) of the U.S. Food & Drug Administration (FDA) received on August 19, 2025, in response to its Premarket Approval (PMA) application for the VenoValve®, a surgical replacement venous valve for treating severe deep chronic venous insufficiency (CVI).
What This Means
Featuring: Nuwellis, Inc.
September 17, 2025
Ryan Marthaler, Vice President of Product Marketing & Business Development of Nuwellis, discussed the Company’s recent news release announcing that the National Institutes of Health (NIH) has awarded an approximately $3 million multi-year grant to its development partner, Koronis Biomedical Technologies Corporation (KBT).
What This Means
Featuring: Autonomix
September 4, 2025
Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses the Company’s recently announced longer-term post hoc analysis results from its proof-of-concept human clinical trial (“PoC 1”) which demonstrated sustained pain reduction, quality of life gains and 100% zero opioid use.
KOL Connect
Featuring: Palisade Bio
August 25, 2025
Moderated discussion with leading expert in Fibrostenotic Crohn’s Disease (FSCD) and Inflammatory Bowel Diseases (IBD), Dr. Brian Feagan
Past Events
New to Virtual Investor
Closing Bell
Closing Bell
Closing Bell
Live What This Means
Closing Bell Series
Live What This Means
Closing Bell Series
Closing Bell Series
Closing Bell Series
Closing Bell Series
Past Events
Join Us
Sign up for email alerts to stay up-to-date on the latest Virtual Investor events
By submitting this form, you are consenting to receive marketing emails from: Virtual Investor. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact